N. prodotti: 0
Totale ordine: € 0,00
Official Journal of the , , , ,
In association with
Indexed/Abstracted in: CINAHL, Current Contents/Clinical Medicine, EMBASE, PubMed/MEDLINE, Science Citation Index Expanded (SciSearch), Scopus
Impact Factor 2,063
Online ISSN 1973-9095
Invernizzi M. 1, 2, Carda S. 3, Molinari C. 4, Stagno D. 5, Cisari C. 1, 2, Baricich A. 2
1 Physical and Rehabilitative Medicine, Department of Health Sciences, University of Eastern Piedmont “A. Avogadro”, Novara, Italy;
2 Department of Physical Medicine & Rehabilitation, University Hospital «Maggiore della Carità», Novara, Italy
3 Department of Neuropsychology and Neurorehabilitation, Centre Hospitalier Universitaire Vaudois (CHUV), Lausanne, Switzerland;
4 Human Physiology, Department of Translational Medicine, University of Eastern Piedmont “A. Avogadro”, Novara, Italy;
5 Department of Neurosciences, University of Genoa, Genoa, Italy
BACKGROUND: The most important adverse effect of BoNT-A is the systemic diffusion of the toxin. There is some evidence that the administration of high doses can increase the risk of systemic diffusion and the development of clinically evident adverse effects, however an international consensus does not exist about its maximum dose.
AIM: The aim of this study was to evaluate changes in autonomic heart drive induced by high doses (higher than 600 units) of incobotulinumtoxinA injection in spastic stroke patients. Moreover, the treatment safety by monitoring adverse events occurrence was assessed.
DESIGN: Case control study.
POPULATION: Eleven stroke survivors with spastic hemiplegia.
METHODS: Patients were treated with intramuscular focal injections of IncobotulinumtoxinA (NT 201; Xeomin®, Merz Pharmaceuticals GmbH, Frankfurt, Germany). Doses were below 12 units/Kg. Each patient underwent an ECG recording before injection and 10 days after treatment. Linear and non-linear Heart Rate variability (HRV) measures were derived from ECGs with a dedicated software.
RESULTS: None of the variable considered showed statistically significant changes after BoNT-A injection.
CONCLUSION: The use of incobotulinumtoxinA in adult patients at doses up to 12 units/kg seems to be safe regarding autonomic heart drive.
CLINICAL REHABILITATION IMPACT: The use of IncobotulinumtoxinA up to 600 units could be a safe therapeutic option in spastic hemiplegic stroke survivors.